Work

Searching for the perfect combination of drug, disease, genetic alteration, and screening test to maximize FGFR inhibition in urothelial cancer

Year: 2020

Type: editorial

Abstract: New targeted therapies to inhibit fibroblast growth factor receptor (FGFR) represent a promising treatment option for patients with metastatic urothelial carcinoma (mUC). Despite significant advances, the optimal combination of drug, disease, genetic alteration, and screening test that together lead to maximal efficacy of FGFR inhibition for patients with mUC remains to be determined.

Source: Cancer

DOI: 10.1002/cncr.32804

Authors: Chelsea K. Osterman, Matthew I. Milowsky

Institutions: University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center

Language: English

Topic: Bladder and Urothelial Cancer Treatments

Subfield: Surgery

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: University of North Carolina, Agency for Healthcare Research and Quality, University of North Carolina at Chapel Hill, Cecil G. Sheps Center for Health Services Research, University of North Carolina, Chapel Hill